HeyJaredPatrick Campbell
- Indexed articles, last 90 days
- 4
- Latest publication
- Oct 1, 2026
- Audience
- Checking…
- Earliest in this view
- Sep 28, 2026
Latest articles
EADV 2026: Tilrekimig Achieves EASI-75 Across All Doses in Atopic Dermatitis | HCPLive (opens the original)
Read excerpt
Frequently Asked Questions:What is tilrekimig?Tilrekimig (PF-07275315) is an investigational trispecific antibody from Pfizer, which simultaneously binds IL-4, IL-13, and TSLP to block multiple drivers of type 2 inflammation. It has not been approved by any regulatory authority.How often is tilrekimig dosed?With a half-life of about 37 days, tilrekimig is designed for monthly administration. Stage 2 of the phase 2 trial evaluated doses of 50 mg to 400 mg every 4 weeks.What did the tilrekimig pha
EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes | HCPLive (opens the original)
Read excerpt
Frequently Asked Questions:What is EloraTZP?EloraTZP is an investigational combination of eloralintide, a once-weekly selective amylin receptor agonist, and tirzepatide, a dual GIP and GLP-1 receptor agonist. It has not been approved by any regulatory authority.How did EloraTZP compare with tirzepatide alone?At 48 weeks, the highest EloraTZP dose reduced body weight by 23.3% and A1C by 2.9%, versus 14.8% and 2.4% with tirzepatide 15 mg, in adults with obesity or overweight and type 2 diabetes.Wh
EADV 2026: Zasocitinib Tops Deucravacitinib for PASI 100 in Plaque Psoriasis | HCPLive (opens the original)
Read excerpt
Frequently Asked Questions:What is zasocitinib?Zasocitinib (TAK-279) is an investigational, once-daily oral TYK2 inhibitor under review by the FDA and European Medicines Agency for moderate to severe plaque psoriasis. It has not been approved by any regulatory authority.How does zasocitinib compare with deucravacitinib?In LATITUDE Atlas, zasocitinib 30 mg once daily produced higher week 16 rates of PASI 100, PASI 90, and sPGA 0 than deucravacitinib 6 mg once daily. Takeda reports zasocitinib has
Weekly Insulin Efsitora Alfa (Onswik) Gains FDA approval for Type 2 Diabetes | HCPLive (opens the original)
Read excerpt
Efsitora is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is not indicated for type 1 diabetes, and its safety and efficacy in children have not been established. Efsitora is injected subcutaneously once weekly on the same day each week. In QWINT-1, insulin-naive adults started at 100 U weekly with fixed escalations to 150 U, 250 U, and 400 U every 4 weeks as needed. Across 4 phase 3 trials in more than 3,400 adults, once-weekly efsito
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.